source
- Aurora Therapeutics halts its custom CRISPR program and cuts staff after competitor Beam moves aheadAurora Therapeutics, a startup developing personalized gene-editing drugs, announced it is abandoning its lead CRISPR program. The decision came just seven months after the company launched, and i…
- Amgen drops early-stage obesity drug candidate AMG-513Amgen announced it is discontinuing its early-stage obesity candidate AMG-513. The program was in Phase 1, but the company provided no details about the study or the reasons for the halt. A spokes…